Decrease of Perforin Expressing Lymphocytes after On-Pump Coronary Artery Bypass Grafting Surgery Irrespective of Carbohydrate Preoperative Oral Feeding
Keywords:Cell immunity, Coronary artery bypass grafting surgery, Oral Feeding, Perforin
Background: Coronary artery bypass grafting (CABG) surgery continues to be the gold standard for treating the patients with coronary artery disease. CABG surgery can be performed on or off cardiopulmonary bypass, termed as on-pump or off-pump CABG, respectively. It has been shown that CABG surgery, preferably on-pump CABG surgery, leads to the changes of cell immunity during perioperative and early postoperative period. The mechanisms of regulation of the immune response in patients during and early after surgical revascularization are not fully understood.
The aim of this study was to investigate the influence of carbohydrate preoperative oral feeding on frequency and perforin expression in peripheral blood lymphocytes in patients after on- or off-pump CABG surgery in early postoperative period.
Patients and methods: In this prospective clinical study, 80 patients scheduled for CABG surgery were included in the study. The patients were randomly allocated into four groups (20 in each group): patients in Group 1 underwent on-pump CABG and did not receive carbohydrate preoperative oral feeding; patients in Group 2 underwent on-pump CABG and were preoperatively fed; patients in Group 3 underwent off-pump CABG and did not receive carbohydrate preoperative oral feeding; while patients in Group 4 underwent off-pump CABG and received carbohydrate preoperative oral feeding. Blood samples were collected immediately before (T1), 24 (T2) and 72 (T3) hours after the surgery. Peripheral blood mononuclear cells were isolated by gradient centrifugation and simultaneously labelled by antigens using fluorochrome-conjugated monoclonal antibodies. Frequency of T lymphocytes, NK and NKT cells, their subsets as well as their perforin expression were detected, and analyzed by flow cytometry.
Results: There was significant decrease in frequency of CD3+ and CD3+CD4+ cells, as well as perforin expressing CD3+CD8+ cells in patients who underwent on-pump CABG in comparison to patients who underwent off-pump CABG 24 hours after the surgery. Carbohydrate preoperative oral feeding did not effect changes in lymphocytes subpopulations and perforin expression at any time point.
Conclusion: Decreases of CD3+ cells on account of CD3+CD4+ subsets, and perforin expressing cells on account of CD3+CD8+ perforin+ cells were found in patients who had undergone on-pump CABG, but not in patients who had undergone off-pump CABG surgery, irrespectively of carbohydrate preoperative oral feeding.
Abbate A, Bussani R, Sinagra G, et al. 2008. Right ventricular cardiomyocyte apoptosis in patients with acute myocardial infarction of the left ventricular wall. Am J Cardiol 102:658-62. Akasaka Y, Morimoto N, Ishikawa Y, et al. 2006. Myocardial apoptosis associated with the expression of proinflammatory cytokines during the course of myocardial infarction. Mod Pathol 19:588-98.
Akbas H, Erdal AC, Demiralp E, Alp M. 2002. Effects of coronary artery bypass grafting on cellular immunity with or without cardiopulmonary bypass: changes in lymphocytes subsets. Cardiovasc Surg 10:586-9.
Allavena P, Giardina G, Bianchi G, Mantovani A. 1997. IL-15 is chemotactic for natural killer cells and stimulates their adhesion to vascular endothelium. J Leukoc Biol 61:729-35.
Anastasilakis CD, Ioannidis O, Gkiomisi AI, Botsios D. 2013. Artificial nutrition and intestinal mucosal barrier functionality. Digestion 88:193-208.
Bujak M, Frangogiannis NG. 2009. The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp (Warsz) 57:165-76.
Buxton BF, Hayward PA. 2013. The art of arterial revascularization-total arterial revascularization in patients with triple vesselcoronary artery disease. Ann Cardiothorac Surg 2:543-51.
Calafiore AM, Di Mauro M, Canosa C, Di Giammarco G, Iaco AL. 2003. Contini M. Myocardial revascularization with and without cardiopulmonary bypass: advantages, disadvantages and similarities. Eur J Cardiothorac Surg 24:953-60.
Chávez-Galán L, Arenas-Del Angel MC, Zenteno E, Chávez R, Lascurain R. 2009. Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol 6:15-25.
Finegold JA, Asaria P, Francis DP. 2012. Mortality from ischaemic heart disease by country, region and age: Statistics from World Health Organisation and United Nations. Int J Cardiol 168:934-45.
Jankovicová K, Kudlová MT, Kolácková M, et al. 2008. The effect of cardiac surgery on peripheral blood lymphocyte populations. Acta Medica (Hradec Kralove) 51:25-9.
Jeremias A, Kaul S, Rosengart TK, Gruberg L, Brown DL. 2009. The impact of revascularization on mortality in patients with nonacute coronary artery disease. Am J Med 122:152-61.
Kazmierski J, Banys A, Latek J, Bourke J, Jaszewski R. 2014. Raised IL-2 and TNF-α concentrations are associated with postoperative delirium in patients undergoing coronary-artery bypass graft surgery. Int Psychogeriatr 26:845-55.
Laskarin G, Zaputovic L, Persic V, Ruzic A, Sotosek Tokmadzic V. 2012. Harmful immune reactions during acute myocardial infarction. Med Hypotheses 78:703-6.
Ludwig RB, Paludo J, Fernandes D, Scherer F. 2013. Lesser time of preoperative fasting and early postoperative feeding are safe? Arq Bras Cir Di 26:54-8.
Martins TB, Anderson JL, Muhlestein JB, et al. 2006. Risk factor analysis of plasma cytokines in patients with coronary artery disease by a multiplexed fluorescent immunoassay. Am J Clin Pathol 125:906-13.
Molfino A, Gioia G, Fanelli FR, Muscaritoli M. 2014. The role for dietary omega-3 fatty acids supplementation in older adults. Nutrients 6:4058-72.
Møller CH, Steinbrüchel DA. 2014. Off-pump versus on-pump coronary artery bypass grafting. Curr Cardiol Rep 16:455.
Orhan G, Sargin M, Senay S, et al. 2007. Systemic and myocardial inflammation in traditional and off pump cardiac surgery. Tex Heart Inst J 34:160-5.
Perera PY, Lichy JH, Waldmann TA, Perera LP. 2012. The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. Microbes Infect 14:247-61.
Persic V, Ruzic A, Miletic B, et al. 2012. Granulysin expression in lymphocytes that populate the peripheral blood and the myocardium after an acute coronary event. Scand J Immunol 78:231-42.
Pipkin ME, Lieberman J. 2007. Delivering the kiss of death: progress on understanding how perforin works. Curr Opin Immunol 19:301-8.
Solomon MD, Tirupsur A, Hytopoulos E, et al. 2013. Clinical utility of a novel coronary heart disease risk-assessment test to further classify intermediate-risk patients. Clin Cardiol 36:621-7.
Subjective Global Assessment of Nutritional Status. http://www.fpnotebook.com/Pharm/Exam/SbjctvGlblAssmntOfNtrtnlSts.htm.
Takagi H, Watanabe T, Mizuno Y, Kawai N, Umemoto T; for the ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. 2014. A meta-analysis of adjusted risk estimates for survival from observational studies of complete versus incomplete revascularization in patients with multivessel disease undergoing coronary artery bypass grafting. Interact Cardiovasc Thorac Surg 18:679-82.
Takayama T, Hiro T, Hirayama A. 2010. Is angioplasty able to become the gold standard of treatment beyond bypass surgery for patients with multivessel coronary artery disease? Therapeutic strategies for 3-vessel coronary artery disease: OPCAB vs PCI (PCI-Side). Circ J 74:2744-9.
Tokmadzic VS, Tsuji Y, Bogovic T, et al. 2002. IL-18 is present at the maternal-fetal interface and enhances cytotoxic activity of decidual lymphocytes. Am J Reprod Immunol 48:191-200.
Windecker S, KolhP, Alfonso F, et al. 2014. 2014 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 34:2541-619.
Zal B, Kaski JC, Akiyu JP, et al. 2008. Differential pathways govern CD4+CD28- T cell proinflammatory and effector responses in patients with coronary artery disease. J Immunol 81:5233-41.
Zuidema MY, Zhang C. 2010. Ischemia/reperfusion injury: The role of immune cells. World J Cardiol 2:325-32.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).